By Ed Frankl

Bayer AG said Tuesday that it "respectfully disagrees" with the U.S. Supreme Court's decision to decline to hear a review of a case that found that the company's weedkiller Roundup may have caused a Calfornia man's cancer.

The German conglomerate said the Supreme Court's decision not to hear a review of a previous case that awarded Edwin Hardeman $25 million undermines the ability of companies to rely on official actions taken by expert regulatory agencies.

A positive result for Bayer at the Supreme Court could have ended thousands of pending lawsuits against the company.

"Bayer continues to stand fully behind its Roundup products which are a valuable tool in efficient agricultural production around the world," it said.

The Leverkusen-based company said it is prepared to manage the litigation risk associated with potential future claims in the U.S.

Bayer took a provision in the second quarter of 2021 of $4.5 billion, in addition to the $2 billion previously taken, it said.

Write to Ed Frankl at edward.frankl@dowjones.com

(END) Dow Jones Newswires

June 21, 2022 10:16 ET (14:16 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Bayer.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Bayer.